AI Article Synopsis
- The study aimed to replicate previous findings linking five specific SNPs to thrombosis in acute lymphoblastic leukemia patients treated with asparaginase.
- Some SNPs, including rs11556218, were found to increase the risk of thrombosis and sensitivity to asparaginase, with variations dependent on treatment protocol and patient characteristics.
- The analysis also revealed interactions between factor V Leiden, non-O blood groups, and an increased risk of thrombosis related to asparaginase treatment.
Article Abstract
We previously conducted exome-wide association study in acute lymphoblastic leukemia patients and identified association of five SNPs with asparaginase-related thrombosis. Here we aimed to replicate these findings in an independent patient cohort and through analyses . SNPs located in , , , and genes were analyzed in patients receiving Dana-Farber Cancer Institute acute lymphoblastic leukemia treatment protocols 05-001 and 11-001. Thrombophilia-related variations were also analysed. rs11556218 conferred higher risk of thrombosis and higher sensitivity to asparaginase. The association was modulated by the treatment protocol, risk group and immunophenotype. A crosstalk between factor V Leiden, non-O blood groups and higher risk of thrombosis was also seen. and factor V Leiden variations are implicated in asparaginase-related thrombosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2022-0164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol
August 2024
Department of Pediatric Hematology, Fujian Medical University, Union Hospital, Fuzhou, China.
Studies on asparaginase enzyme activity (AEA) monitoring in Chinese patients receiving PEG-asparaginase remain limited. We monitored AEA in paediatric patients diagnosed with acute lymphoblastic leukaemia (ALL) and treated according to the Chinese Children's Cancer Group study protocols, CCCG-ALL-2015/CCCG-ALL-2020 protocols. We measured the AEA at days 7 ± 1 and 14 ± 1 and analysed their association with patient characteristics and PEG-asparaginase-related adverse effects (AEs).
View Article and Find Full Text PDFAsparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.
Expert Opin Drug Metab Toxicol
November 2023
School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
Introduction: Asparaginase is essential to chemotherapy regimens for acute lymphoblastic leukemia (ALL). Survival of patients with ALL has improved since incorporating asparaginase into chemotherapy backbones. Hispanic patients have a higher incidence of ALL than other ethnicities and suffer inferior outcomes.
View Article and Find Full Text PDFand factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients.
Pharmacogenomics
March 2023
Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Montreal, QC, H3T 1C5, Canada.
Article Synopsis
- The study aimed to replicate previous findings linking five specific SNPs to thrombosis in acute lymphoblastic leukemia patients treated with asparaginase.
- Some SNPs, including rs11556218, were found to increase the risk of thrombosis and sensitivity to asparaginase, with variations dependent on treatment protocol and patient characteristics.
- The analysis also revealed interactions between factor V Leiden, non-O blood groups, and an increased risk of thrombosis related to asparaginase treatment.
[Analysis of 8 cases of asparaginase related cerebral venous sinus thrombosis in children].
Zhonghua Er Ke Za Zhi
June 2022
Department of Hematology and Oncology, Children's Hospital, the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China.
To summarize the clinical features, treatment and prognosis of asparaginase (ASP) related cerebral venous sinus thrombosis (CVST). Clinical profiles including age, sex, first symptoms, coagulation function, imaging findings, ASP type, treatment and prognosis of eight acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) children with ASP related CVST at the Department of Pediatrics, First Affiliated Hospital of Zhengzhou University from November 2016 to October 2021 were analyzed retrospectively. Eight CVST children were all male, including 6 ALL and 2 LBL, with the onset age ranged from 5 to 15 years, 6 cases occurred in the stage of first induction remission, and the initial symptom were mainly epileptic seizures (7 cases).
View Article and Find Full Text PDFManagement Practices for Asparaginase-associated Coagulopathy: A Survey of Pediatric Oncologists.
J Pediatr Hematol Oncol
November 2022
Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN.
Background: Coagulopathy and thrombosis are well-described complications of asparaginase therapy. However, treatment practices in pediatric hematology/oncology (PHO) patients vary widely as evidence-based guidelines for clinical management of these complications in this population are lacking.
Objective: The objective of this study was to assess management practices of asparaginase-related coagulopathy by pediatric hematologist/oncologist attending physicians.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!